Zimmer Biomet Holdings (0QQD) Price & Analysis

1 Followers

0QQD Stock Chart & Stats

CHF77.38

CHF0.00(0.00%)

At close: Jul 27 4:00 PM EDT

CHF77.38

CHF0.00(0.00%)

Day’s Range― - ―

52-Week RangeCHF77.38 - CHF77.38

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

CHF14.70B

Enterprise ValueCHF24.76K

Total Cash (Recent Filing)CHF424.20M

Total Debt (Recent Filing)CHF7.47B

Price to Earnings (P/E)24.3

Beta>-0.01

Next Earnings

Nov 04, 2026

EPS Estimate

1.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.87

Shares Outstanding193,462,480

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-1.26

Price to Book (P/B)1.40

Price to Sales (P/S)2.16

P/FCF Ratio12.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF80.52

Price Target Upside4.06% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

EPS Forecast (FY)6.88

Revenue Forecast (FY)CHF6.93B

Bulls Say, Bears Say

Bulls Say

High Gross And EBITDA MarginsSustained high gross and EBITDA margins indicate durable operating leverage and pricing/production efficiency in implant and consumable portfolios. That margin buffer supports continued R&D and robotics investment, cushions against modest price erosion, and helps fund capital returns and M&A over the medium term.

Robotics And Technology MomentumAccelerating adoption of robotics, digital tools and high‑margin consumables shifts revenue mix toward recurring and higher‑growth areas. Completion of Monogram enrollment and strong ROSA/TMINI uptake underpin a multi‑year commercial ramp, expanding addressable market and creating stickier surgeon/hospital relationships.

Improved Liquidity And Credit FlexibilityProactive refinancing expands available liquidity and preserves strategic optionality for acquisitions, working capital, and share repurchases. Five‑year facility with covenant room provides resilience against cyclical shocks and supports multi‑year investments in robotics and international go‑to‑market shifts.

Bears Say

Compressed Net Margin And Weak ROEFalling net margins and weakened ROE signal reduced bottom‑line efficiency versus prior years, limiting returns on invested capital. Even with strong gross margins, pressure on net income reduces retained earnings growth and constrains long‑term capital allocation flexibility and shareholder returns.

Negative Free Cash Flow Growth And Cash VolatilitySharp negative FCF growth and operating cash flow variability suggest working‑capital or timing pressures that undermine consistent cash conversion. This raises risk to funding buybacks, debt service, and robotics rollouts if operating momentum weakens, and increases sensitivity to any margin deterioration.

Commercial Transition And Product HeadwindsA multi‑year U.S. salesforce transformation and legacy knee phase‑out create persistent execution risk as account relationships and surgeon preference can shift. Lost large accounts and underperformance in key portfolios may allow competitors to gain share, slowing durable revenue recovery during the transition.

Zimmer Biomet Holdings News

Zimmer Biomet raises FY26 adjusted EPS view to $8.47-$8.59 from $8.40-$8.55

Consensus $8.47. Raises FY26 revenue view to up 3.9%-4.9% from 2.5%-4.5%. Published first on TheFly – the ultimate...

4h ago

ZBH

Zimmer Biomet reports Q2 adjusted EPS $2.07, consensus $2.01

Reports Q2 revenue $2.18B, consensus $2.14B. “We delivered strong second quarter results with solid top- and bottom-line performance...

4h ago

ZBH

Intuit downgrade, Intuitive Surgical upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

8d ago

Zimmer Biomet upgraded to Buy from Sell at UBS

UBS analyst Patrick Wood upgraded Zimmer Biomet (ZBH) to Buy from Sell with a price target of $115,...

8d ago

ZBH

Conmed offers could be in $46-$53 per share range, says Needham

Needham keeps a Hold rating on Conmed (CNMD) after Bloomberg reported the company has been exploring a possible...

23d ago

ZBH

CNMD

BMO starts Zimmer at Market Perform, says valuation appears attractive

BMO Capital analyst Vik Chopra initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $95...

28d ago

ZBH

Zimmer Biomet initiated with a Market Perform at BMO Capital

BMO Capital initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $95 price target Published...

28d ago

ZBH

Zimmer Biomet Holdings (ZBH) Q2 Earnings Cheat Sheet

Zimmer Biomet Holdings (ZBH) is scheduled to report 2nd quarter earnings on 08/05/2026, before the market opens. Regarding...

2d ago

ZBH

Zimmer Biomet: Solid Orthopedics Franchise and Early-Stage Digital Investments Support Neutral Risk-Reward, Justifying Hold Rating

BTIG analyst Ryan Zimmerman has maintained their neutral stance on ZBH stock, giving a Hold rating on July...

12d ago

ZBH

Zimmer Biomet’s Mymobility Knee ROM Study Signals Growing Digital Edge in Joint Care

Zimmer Biomet Holdings ($ZBH) announced an update on their ongoing clinical study. The study “Concordance Between an App-based...

26d ago

ZBH

Zimmer Biomet Kept at Hold as Analyst Awaits Proof of Salesforce Overhaul, Margin Stability and Robotics‑Driven Upside

, an analyst from BMO Capital, has initiated a new Hold rating on Zimmer Biomet Holdings (ZBH). analyst...

28d ago

ZBH

Zimmer Biomet price target lowered to $110 from $120 at Evercore ISI

Evercore ISI lowered the firm’s price target on Zimmer Biomet (ZBH) to $110 from $120 and keeps an...

1M ago

ZBH

AI Models Turn More Positive on Zimmer Biomet as Guidance and Cash Flow Improve

Zimmer Biomet Holdings (ZBH) received upgraded scores from three AI models on TipRanks, reflecting improved confidence in the...

1M ago

ZBH

Pacira Zimmer to divest iovera degrees to Biomet for $70M upfront

Pacira (PCRX) announced the divestiture of iovera degrees to Zimmer Biomet (ZBH). The iovera degrees system is a...

1M ago

ZBH

PCRX

0QQD FAQ

What was Zimmer Biomet Holdings’s price range in the past 12 months?

Zimmer Biomet Holdings lowest share price was CHF77.38 and its highest was CHF77.38 in the past 12 months.

What is Zimmer Biomet Holdings’s market cap?

Zimmer Biomet Holdings’s market cap is CHF14.70B.

When is Zimmer Biomet Holdings’s upcoming earnings report date?

Zimmer Biomet Holdings’s upcoming earnings report date is Nov 04, 2026 which is in 91 days.

How were Zimmer Biomet Holdings’s earnings last quarter?

Zimmer Biomet Holdings released its earnings results on Aug 05, 2026. The company reported CHF1.674 earnings per share for the quarter, beating the consensus estimate of CHF1.625 by CHF0.049.

Is Zimmer Biomet Holdings overvalued?

According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Zimmer Biomet Holdings pay dividends?

Zimmer Biomet Holdings does not currently pay dividends.

What is Zimmer Biomet Holdings’s EPS estimate?

Zimmer Biomet Holdings’s EPS estimate is 1.52.

How many shares outstanding does Zimmer Biomet Holdings have?

Zimmer Biomet Holdings has 193,462,480 shares outstanding.

What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?

Zimmer Biomet Holdings reported an EPS of CHF1.674 in its last earnings report, beating expectations of CHF1.625. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Zimmer Biomet Holdings?

Currently, no hedge funds are holding shares in GB:0QQD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Zimmer Biomet Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

1.06%

Trailing 12-Months

Asset Growth

2.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Zimmer Biomet Holdings (0QQD) Earnings & Revenues

Historic Earnings Reports

0QQD Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call presented more positive developments than negative ones: solid top‑line growth (reported and organic), an EPS beat and raised EPS and free cash flow guidance, strong cash generation, accelerating performance from strategic acquisitions (Paragon 28) and clear momentum in technology and robotics (Monogram enrollment complete, ROSA/TMINI adoption). Offsetting items include short‑term disruption from the U.S. salesforce transformation and legacy knee transitions, some international go‑to‑market disruption, a one‑time tariff benefit that partially pulled forward upside, and higher interest expense tied to acquisition debt. On balance the company appears to be executing on its strategic priorities while managing expected transitional headwinds.View all GB:0QQD earnings summaries

0QQD Net sales Breakdown

40.36% Knees

25.43% Hips

26.12% S.E.T

8.09% Technology & Data, Bone Cement and Surgical

0QQD Stock 12 Month Forecast

Average Price Target

CHF80.52

▲(4.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"66":"CHF66","73":"CHF73","80":"CHF80","87":"CHF87","94":"CHF94"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":93.0143023,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF93.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.52252643555556,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF80.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.13206166,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF67.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[66,73,80,87,94],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.376,78.57894633076924,79.78189266153846,80.9848389923077,82.18778532307692,83.39073165384616,84.59367798461538,85.79662431538462,86.99957064615384,88.20251697692308,89.4054633076923,90.60840963846154,91.81135596923076,{"y":93.0143023,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.376,77.61804049504273,77.86008099008548,78.10212148512821,78.34416198017095,78.58620247521368,78.82824297025641,79.07028346529916,79.31232396034189,79.55436445538461,79.79640495042736,80.03844544547009,80.28048594051283,{"y":80.52252643555556,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.376,76.58800474307692,75.80000948615385,75.01201422923077,74.2240189723077,73.43602371538462,72.64802845846154,71.86003320153847,71.07203794461539,70.2840426876923,69.49604743076924,68.70805217384616,67.92005691692309,{"y":67.13206166,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":77.376,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.376,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >